The company anticipates 2025 revenue to be in the range of $58.0 billion to $61.0 billion, growth of 32% at the midpoint compared to expected 2024 revenue ...

As the conference kicked off, deals were announced from Eli Lilly (LLY), Johnson & Johnson ... exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second presidency. The ...

The lawmakers also say that a Cures 2.1 push should include an update to the government’s clinical trial website to enable ... data submitted by each pharmaceutical company and explain how ...

Oncology Cancer Drugs Market With a projected ... Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold ...

Eli Lilly has launched a new website-based access ... diabetes and migraine drugs, respectively, via telehealth providers 9amHealth and Cove. According to the company, it allows “consistent ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing ...

Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

the effects of Medicare’s drug price negotiation, Lilly’s recent disappointing guidance, pricing of the company’s obesity medication Zepbound, and more. We also discuss the latest news from ...